(Total Views: 296)
Posted On: 09/25/2018 10:07:27 AM
Post# of 72440
I have appealed the removal of this post I made this morning at IHUB.
Post Date: 9/25/2018 8:41:03 AM in reply to 143768912 by georgejjl
Board: Innovation Pharmaceuticals Inc. Reason: Off-Topic
George: Thanks for your continuing P posts. I smiled yesterday remembering your belief that P could be a 10-15 billion dollar drug. I thought of that as I read this CITI anylist's comment about AMRN which opened yesterday @ $2.99 and closed at $12.40.
Citi sees another 5x upside in Amarin
Sep. 24, 2018 11:53 AM ET|By: Stephen Alpher, SA News Editor
Amarin (NASDAQ:AMRN) has skyrocketed more than 200% to $10.15 today after its fish oil capsule showed big benefits in a trial of more than 8K patients with elevated risk of heart issues.
Assuming the expanded REDUCE-IT label is granted, Citi sees peak sales of a whopping $2.7B. That assumes only about 2M of the 50B-70B eligible patients are treated. The team there sees upside to $50 per share, with Amarin being a strong acquisition target. Source: Notable Calls
Also on the move on the news is Acasti Pharma (ACST +26.9%), whose heart pill candidate CaPre is mostly made up of omega-3 fatty acids.
Previously: Amarin reports positive results from REDUCE-IT study; shares up 307% premarket (Sept. 24)
If they are worth $50.00 in a buyout with a single drug just imagine what we will be worth with multiple blockbusters! Just goes to show how undervalued we are at this time. Go IPIX!!!
Post Date: 9/25/2018 8:41:03 AM in reply to 143768912 by georgejjl
Board: Innovation Pharmaceuticals Inc. Reason: Off-Topic
George: Thanks for your continuing P posts. I smiled yesterday remembering your belief that P could be a 10-15 billion dollar drug. I thought of that as I read this CITI anylist's comment about AMRN which opened yesterday @ $2.99 and closed at $12.40.
Citi sees another 5x upside in Amarin
Sep. 24, 2018 11:53 AM ET|By: Stephen Alpher, SA News Editor
Amarin (NASDAQ:AMRN) has skyrocketed more than 200% to $10.15 today after its fish oil capsule showed big benefits in a trial of more than 8K patients with elevated risk of heart issues.
Assuming the expanded REDUCE-IT label is granted, Citi sees peak sales of a whopping $2.7B. That assumes only about 2M of the 50B-70B eligible patients are treated. The team there sees upside to $50 per share, with Amarin being a strong acquisition target. Source: Notable Calls
Also on the move on the news is Acasti Pharma (ACST +26.9%), whose heart pill candidate CaPre is mostly made up of omega-3 fatty acids.
Previously: Amarin reports positive results from REDUCE-IT study; shares up 307% premarket (Sept. 24)
If they are worth $50.00 in a buyout with a single drug just imagine what we will be worth with multiple blockbusters! Just goes to show how undervalued we are at this time. Go IPIX!!!
(5)
(0)Scroll down for more posts ▼
